Tiverton Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Tiverton Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-970	Closed	-$399K	–	721
2019 Q1	$399K	Buy	+970	New	+$399K	0.02%	403
2018 Q2	–	Sell	-787	Closed	-$271K	–	492
2018 Q1	$271K	Sell	787 -324	-29%	-$113K	0.02%	281
2017 Q4	$418K	Buy	+1,111	New	+$450K	0.03%	257
2017 Q1	–	Sell	-2,093	Closed	-$769K	–	198
2016 Q4	$769K	Hold	2,093	–	–	0.05%	175
2016 Q3	$842K	Buy	+2,093	New	+$840K	0.07%	141

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Tiverton Asset Management's REGN Position: Q2 2019 in Review

Tiverton Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2019, closing a stake of 970 shares — an estimated $399K sold.

Tiverton Asset Management first reported a position in REGN in Q3 2016 and held it in 5 quarters. The position peaked at $842K in Q3 2016. 658 funds tracked by Wall St. Rank hold REGN as of Q2 2019.

Tiverton Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Tiverton Asset Management sold 970 Regeneron Pharmaceuticals shares in Q2 2019, an estimated $399K.
Tiverton Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2016 and held it in 5 quarters.
Tiverton Asset Management's Regeneron Pharmaceuticals position peaked at $842K in Q3 2016.
658 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2019.

Based on Tiverton Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.